Company insight Fast moving technology
With an understanding that a ‘one size fits all’ approach to medicine does not necessarily work, Stäubli Robotics has leveraged its position as a pioneering force in pharmaceutical robotics to assist its partners in biopharmaceutical development to produce more personalised forms of medicine.
s a major challenge for public health, biopharmaceuticals are particularly useful for treating chronic diseases such as cancers. These techniques are part of the research of personalised medicine: a given medication, with the same dose, doesn’t suit everyone.
A
In order to reduce the production time and increase yields, automation turns out to be a major ally. Stäubli Robotics has supported its customers that are specialised in biotherapies since 1993, launching the cellmate machine using a Puma robot to produce such biotech drug. “Robotics will help the scalability of production of personalised medicine with the goal of reducing costs for the patient,” says Sebastien Lagarde, global market leader, pharma and medical.
A new era of industrialisation Personalised medicine is a small batch production, or even unique batch production. It is now necessary to have equipment with more flexible arms and small insulators for capacity. The robot is placed at the centre of production and manages all operations. Small batch equipment trends are expected to follow the rest of the process to the logistics area in the future, with small batch inspection machines and small batch packaging machines.
Stäubli Robotics’ expertise in pharmaceutical robotics puts its partners at significant advantage.
world is entering a new era of industrialisation, with the main objective of scaling up by producing batches in parallel. One solution is to increase the size of the robots. This makes it possible to multiply the ‘cell and gene therapy management’ stations, limiting the scaling up of production around the robot and compensating for the lack of mobile robots today.
The most important risk being cross- contamination, automation solutions and defined rules for the manufacture of sterile drugs (Annex 1, EU GMP) tend to reduce this risk. Robots used for this technology should be aligned with these Good Manufacturing Practices and FDA compliant
“Robotics will help the scalability of production of personalised medicine with the goal of reducing cost for the patient.”
“For this configuration, the robot is very popular thanks to its small size and its flexibility to adapt to each product to be handled,” explained Lagarde. “In addition, the use of a tool changer is now mandatory.” However, producing drugs for a single patient has a cost. The pharmaceutical
materials to build end-user confidence. With the boom of biotherapies and growing expectations for personalised medicine, innovative robotics devices will shape the factory of a future more flexible and safer, opening the door to Autonomous Mobile Robotics.
World Pharmaceutical Frontiers /
www.worldpharmaceuticals.net Stäubli Robotics
Stäubli Robotics is a global player in the industrial automation sector. Its place as a pioneer in pharmaceutical robotics in aseptic environments and its 30 years of experience in this market have enabled Stäubli to develop a complete pharmaceutical offer of four and six-axis robots including the Stericlean range and the Stericlean+ range. Each range is adapted to the ever-increasing requirements of the pharmaceutical sector by providing validated solutions that meet the highest hygiene and sterility standards. ●
www.staubli.com 25
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61
